Investors Overview
We’re Delivering the Promise of Healthier Lives.
Our Company
Corporate Profile
CURE has an FDA-registered, cGMP manufacturing facility and is a pioneering developer of CUREform™, a patented drug delivery platform which includes CUREfilm®, one of the most advanced oral thin films on the market today; CUREpods™ a novel chewable delivery system and other more traditional dose forms that use advanced encapsulation technology. CUREform’s combined technologies provide opportunities for both immediate and controlled-release drug delivery of a wide range of active ingredients. CURE also holds the NSF® cGMP certification for manufacturing dietary supplements.
CURE’s clinical pipeline includes CUREfilm® Blue (sildenafil to treat erectile dysfunction), and CUREfilm® Canna (THC and CBD) each designed to optimize the pharmacokinetic profile of the medicine.
CURE partners with biotech, pharmaceutical, and wellness companies worldwide and has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector, with partnerships in the U.S.A, Canada, Israel, and other markets.
Cure Pharmaceutical Corporation was founded in July 2011 and is a wholly-owned subsidiary of Cure Pharmaceutical Holding Corp, a public company.
Stock Today
Headquarters
CURE Pharmaceutical
1620 Beacon Place
Oxnard, CA 93033
Phone:
Fax:
We are positioned to advance numerous therapeutic categories, including pharmaceutical cannabis.
Cure Pharmaceutical
Our Investor Presentation
Media
Recent Videos
CURE Pharmaceutical Investor
Video Webcast | Dec. 17 2020
CBD, Cannabis and the Cannabiz
In the news
Press Releases
CURE Pharmaceutical to Present at the 2021 Sequire Cannabis Conference on Tuesday, April 20, at 2 p.m. EDT/11 a.m. PDT
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that Rob Davidson, CURE's Chief Executive Officer, and Nancy Duitch, CEO of subsidiary Sera Labs and Chief Strategic...
Nicole Kidman, Sera Labs Strategic Business Partner/Global Brand Ambassador and Nancy Duitch, Sera Labs Founder/CEO Headline Collision 2021
LOS ANGELES--(BUSINESS WIRE)--Sera Labs, a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), announced today that Academy Award, Golden Globe and Emmy Award-winning actor/producer/entrepreneur Nicole Kidman and Sera Labs CEO/CURE Pharmaceutical Chief...
CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020
Fiscal Year 2020 Highlights: Generated dramatic growth in total and pro forma revenue Released positive clinical data on its patented drug delivery technology and received new certifications at its research facility Acquired and expanded consumer wellness subsidiary...
CURE Pharmaceutical Launches Psychedelic Oral Film Program Targeting the Treatment of Mental Health Disorders
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. ("CURE" or the "Company") (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has launched a new initiative for the clinical development of psychedelic compounds...
CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. ("CURE" or the "Company") (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has launched two new clinical development programs and added new corresponding...
CURE Pharmaceutical’s Subsidiary Sera Labs Launches National Television, Radio & Digital Advertising Campaign for Nutri-Strips Sleep A.S.A.P.
Sleep A.S.A.P. provides proof of concept and monetization for CURE's patented oral thin-film technology LOS ANGELES & OXNARD, Calif. - CURE Pharmaceutical Holding Corp. ("CURE" or the "Company") (OTC: CURR), a technology focused, vertically integrated drug...
Management Team
Board of Directors
Key Contacts
Investor Relations
(805) 410-9962 ext. 4
investor@curepharma.com
Transfer Agent
Continental Stock Transfer & Trust
1 State Street 30th Floor
New York, NY 10004-1561
www.continentalstock.com
Auditors
RBSM, LLP
805 3rd Avenue #1430
New York, NY 10022
Corporate Counsel
Stradling Yocca Carlson & Rauth
660 Newport Center Drive
Suite 1600
Newport Beach, CA 92660
T: 949-725-4000
F: 949-725-4100